Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | TCS PIM-1 1 | Pim kinase | PIM | 12319.135 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.3806 | |
| LY2 | HR+ | Luminal | TCS PIM-1 1 | Pim kinase | PIM | 10816.148 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.7402 | |
| MDA-MB-415 | HR+ | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 9664.049 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.7193 | |
| Hs 578T | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7861.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.8485 | |
| MDA-MB-175-VII | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7884.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.6074 | |
| Hs 578T | TNBC | Basal B | Baicalein | Lipoxygenase | Metabolism | 7472.072 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 1.2269 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 10077.026 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.3999 | |
| MDA-MB-415 | HR+ | Luminal | AS-252424 | PI3K | PI3K | 10938.153 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.4228 | |
| HCC1569 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 7824.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 1.3115 | |
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 7473.091 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 2.3297 | |
| HCC1806 | TNBC | Basal A | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 7450.095 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 1.7844 | |
| SUM1315MO2 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 9044.084 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.4769 | |
| BT-20 | TNBC | Basal A | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5902.095 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 1.0245 | |
| SUM185PE | TNBC | Luminal | Cetuximab | EGFR | ErbB | 10146.124 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.9296 | |
| MCF 10A | NM | Basal B | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 7483.095 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 2.6732 | |
| MDA-MB-361 | HER2amp | Luminal | GW843682X | PLK | PLK | 10643.139 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.6402 | |
| LY2 | HR+ | Luminal | ZM-447439 | AURK | AURK | 10816.15 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.3031 | |
| LY2 | HR+ | Luminal | PS-1145 | IKK | NFKB | 7477.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.7891 | |
| AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7794.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 1.6812 | |
| MDA-MB-415 | HR+ | Luminal | Selumetinib | MEK | MAPK | 10938.155 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.5336 | |
| SUM1315MO2 | TNBC | Basal B | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 7528.095 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.8526 | |
| MDA-MB-415 | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 10938.072 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.5611 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 9254.049 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.8730 |